[1] |
World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
|
[2] |
Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182(5):684-692.
doi: 10.1164/rccm.201001-0077OC
URL
|
[3] |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
|
[4] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi:10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001.
|
[5] |
World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
|
[6] |
Nie Q, Tao L, Li Y, et al. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB. Int J Infect Dis, 2022, 115(2):142-148. doi:10.1016/j.ijid.2021.11.037.
doi: 10.1016/j.ijid.2021.11.037.
URL
|
[7] |
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, et al. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [2017-07]. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
|
[8] |
Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J, 2020, 55(3):1901467. doi:10.1183/13993003.01467-2019.
doi: 10.1183/13993003.01467-2019.
URL
|
[9] |
Aung KJ, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014, 18(10):1180-1187. doi:10.5588/ijtld.14.0100.
doi: 10.5588/ijtld.14.0100
pmid: 25216831
|
[10] |
Wahid A, Ghafoor A, Khan AW, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol, 2022, 13(9):973713. doi:10.3389/fphar.2022.973713.
doi: 10.3389/fphar.2022.973713.
URL
|
[11] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019, 380(13):1201-1213. doi:10.1056/NEJMoa1811867.
doi: 10.1056/NEJMoa1811867.
URL
|
[12] |
Lempens P, Decroo T, Aung KJM, et al. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. Int J Infect Dis, 2020, 100(11):357-365. doi:10.1016/j.ijid.2020.08.042.
doi: 10.1016/j.ijid.2020.08.042.
URL
|
[13] |
Piubello A, Souleymane MB, Hassane-Harouna S, et al. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. Respir Med, 2020, 161(1):105844. doi:10.1016/j.rmed.2019.105844.
doi: 10.1016/j.rmed.2019.105844.
URL
|
[14] |
Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med, 2020, 8(4):383-394. doi:10.1016/S2213-2600(20)30047-3.
doi: 10.1016/S2213-2600(20)30047-3
pmid: 32192585
|
[15] |
《中国防痨杂志》编辑委员会. 耐药结核病化疗过程中药品不良反应处理的专家共识. 中国防痨杂志, 2019, 41(6): 591-603. doi:10.3969/j.issn.1000-6621.2019.06.003.
doi: 10.3969/j.issn.1000-6621.2019.06.003.
|
[16] |
Chee CBE, KhinMar KW, Sng LH, et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Eur Respir J, 2017, 50(2):1700753. doi:10.1183/13993003.00753-2017.
doi: 10.1183/13993003.00753-2017.
URL
|
[17] |
van der Werf MJ, Hollo V, Ködmön C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J, 2017, 49(3):1601992. doi:10.1183/13993003.01992-2016.
doi: 10.1183/13993003.01992-2016.
URL
|
[18] |
Tsang CA, Shah N, Armstrong LR, et al. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011—2016. Clin Infect Dis, 2020, 70(5):907-916. doi:10.1093/cid/ciz263.
doi: 10.1093/cid/ciz263.
|
[19] |
陈蓉, 李马超, 赵丽丽, 等. 167株耐多药结核分枝杆菌药物敏感谱分析. 中华流行病学杂志, 2020, 41(5): 764-769. doi:10.3760/cma.j.cn112338-20191121-00823.
doi: 10.3760/cma.j.cn112338-20191121-00823.
|
[20] |
金龙, 田琦, 张宝庆, 等. 荧光PCR熔解曲线法检测耐多药肺结核患者对左氧氟沙星和莫西沙星耐药性的效能研究. 中国防痨杂志, 2022, 44(2): 159-163. doi:10.19982/j.issn.1000-6621.20210488.
doi: 10.19982/j.issn.1000-6621.20210488.
|
[21] |
邝浩斌, 谭守勇, 梁敏青, 等. 耐多药肺结核患者并发气管支气管结核的相关性研究. 中国防痨杂志, 2017, 39(3): 242-246. doi:10.3969/j.issn.1000-6621.2017.03.007.
doi: 10.3969/j.issn.1000-6621.2017.03.007.
|
[22] |
唐神结, 高文, 临床结核病学. 北京: 人民卫生出版社, 2019.
|
[23] |
国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.
doi: 10.3969/j.issn.1000-6621.2021.01.004.
|
[24] |
Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014, 18(10):1188-1194. doi:10.5588/ijtld.13.0075.
doi: 10.5588/ijtld.13.0075
pmid: 25216832
|
[25] |
Trubnikov A, Hovhannesyan A, Akopyan K, et al. Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis. Int J Environ Res Public Health, 2021, 18(8):4121. doi:10.3390/ijerph18084121.
doi: 10.3390/ijerph18084121.
URL
|
[26] |
李琦, 李亮. 耐多药或利福平耐药结核病长程化疗方案与短程化疗方案的利与弊. 中华结核和呼吸杂志, 2019, 42(5):333-338. doi:10.3760/cma.j.issn.1001-0939.2019.05.005.
doi: 10.3760/cma.j.issn.1001-0939.2019.05.005.
|